Φορτώνει......
PRDM1 is required for Mantle Cell Lymphoma response to Bortezomib
Mantle cell lymphoma (MCL) is an aggressive form of B cell lymphoma with a poor disease- free survival rate. The proteasome inhibitor, Bortezomib, is approved for treatment of relapsed and refractory MCL and has efficacy in about 30% of patients. However, the precise mechanism of action of Bortezomi...
Αποθηκεύτηκε σε:
| Κύριοι συγγραφείς: | , , , , , , , |
|---|---|
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
2010
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2891394/ https://ncbi.nlm.nih.gov/pubmed/20530581 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1541-7786.MCR-10-0131 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|